miR‑421 promotes the viability of A549 lung cancer cells by targeting forkhead box O1

Mo,Xiao-Mei; Qin,Peng-Fei; Wang,Bing; Liu,Feng-Hai; Li,Hua-Hui

doi:10.3892/ol.2020.12169

miR‑421 promotes the viability of A549 lung cancer cells by targeting forkhead box O1

Authors:
- Xiao-Mei Mo
- Peng-Fei Qin
- Bing Wang
- Feng-Hai Liu
- Hua-Hui Li
View Affiliations

Affiliations: Pharmacy Department, Qingdao Women and Children's Hospital, Qingdao University, Qingdao, Shandong 266034, P.R. China, Department of Laboratory Medicine, Qingdao Municipal Hospital, Qingdao, Shandong 266071, P.R. China
Published online on: September 29, 2020 https://doi.org/10.3892/ol.2020.12169
Article Number: 306
Copyright: © Mo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑421 has been reported to serve various important roles in numerous types of cancer, including neuroblastoma and gastric cancer. However, to the best of our knowledge, few reports have determined the role of miR‑421 in lung cancer. The aim of the current study was to analyze the expression levels of miR‑421 in A549 lung cancer cells, to determine the target gene of miR‑421, and to investigate the function and mechanism of miR‑421 in cellular cytotoxicity. miR‑421 expression levels were analyzed in A549 lung cancer cells using reverse transcription‑quantitative PCR, a MTT assay was performed to determine the effect of miR‑421 on A549 cell cytotoxicity and the protein expression levels of forkhead box O1 (FOXO1) were determined via western blotting. The target gene of miR‑421 was predicted and verified using TargetScan and a dual‑luciferase reporter assay, respectively. The results revealed that miR‑421 expression levels were significantly upregulated in A549 lung cancer cell lines compared with the normal cells (P<0.01). Additionally, it was discovered that miR‑421 promoted A549 cell viability (P<0.01) compared with A549 transfected with negative control. miR‑421 was also identified to bind to the 3'‑untranslated region of FOXO1. In A549 cells transfected with miR‑421‑mimics, the expression levels of phosphorylated (p)‑AKT, p‑glycogen synthase kinase‑3β, p‑retinoblastoma and cyclin D1 were significantly upregulated (P<0.01), whereas the expression levels of FOXO1 and p21 were significantly downregulated (P<0.01) compared with the control group. In conclusion, the results of the present study suggested that miR‑421 may promote the viability of A549 lung cancer cells by targeting FOXO1 and modulating cell cycle, indicating that targeting miR‑421 and FOXO1 may represent future therapeutic strategies for the treatment of patients with lung cancer.

View Figures

View References

1	Zhou C, Zhu Y, Lu B, Zhao W and Zhao X: Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine. Oncol Lett. 16:5466–5472. 2018.PubMed/NCBI
2	Chen Z, Wang J, Bai Y, Wang S, Yin X, Xiang J, Li X, He M, Zhang X, Wu T, et al: The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer. Cancer Gene Ther. 24:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
3	Joshi M, Ayoola A and Belani CP: Small-cell lung cancer: An update on targeted. Adv Exp Med Bio. 779:385–404. 2013. View Article : Google Scholar
4	Carter BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA and de Groot PM: Immunotherapy in non-small cell lung cancer treatment: Current status and the role of imaging. J Thorac Imaging. 32:300–312. 2017. View Article : Google Scholar : PubMed/NCBI
5	Li L, Sun Y, Feng M, Wang L and Liu J: Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer. Oncol Lett. 15:8915–8925. 2018.PubMed/NCBI
6	Lu J, Zhan Y, Feng J, Luo J and Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sc. 14:390–397. 2018. View Article : Google Scholar
7	Guarize J, Bianchi F, Marino E, Belloni E, Vecchi M, Donghi S, Lo Iacono G, Casadio C, Cuttano R, Barberis M, et al: MicroRNA expression profile in primary lung cancer cells lines obtained by endobronchial ultrasound transbronchial needle aspiration. J Thorac Dis. 10:408–415. 2018. View Article : Google Scholar : PubMed/NCBI
8	Iqbal MA, Arora S, Prakasam G, Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance. Mol Aspects Med. 70:3–20. 2019. View Article : Google Scholar : PubMed/NCBI
9	Seok H, Ham J, Jang ES and Chi SW: MicroRNA Target Recognition: Insights from Transcriptome-Wide Non-Canonical Interactions. Mol Cells. 39:375–381. 2016. View Article : Google Scholar : PubMed/NCBI
10	Isik M, Blackwell TK and Berezikov E: MicroRNA mir-34 provides robustness to environmental stress response via the DAF-16 network in C. elegans. Sci Rep. 6:367662016. View Article : Google Scholar : PubMed/NCBI
11	Wojciechowska A, Braniewska A and Kozar-Kamińska K: MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med. 26:865–874. 2017. View Article : Google Scholar : PubMed/NCBI
12	Tran N: Cancer Exosomes as miRNA Factories. Trends Cancer. 2:329–331. 2016. View Article : Google Scholar : PubMed/NCBI
13	Wang JK, Wang Z and Li G: MicroRNA-125 in immunity and cancer. Cancer Lett. 454:134–145. 2019. View Article : Google Scholar : PubMed/NCBI
14	Chen YL, Xu QP, Guo F and Guan WH: MicroRNA-302d downregulates TGFBR2 expression and promotes hepatocellular carcinoma growth and invasion. Exp Ther Med. 13:681–687. 2017. View Article : Google Scholar : PubMed/NCBI
15	An X, Sarmiento C, Tan T and Zhu H: Regulation of multidrug resistance by microRNAs in anti-cancer therapy. Acta Pharm Sin B. 7:38–51. 2017. View Article : Google Scholar : PubMed/NCBI
16	Li Y, Li W, Zhang JG, Li HY and Li YM: Downregulation of tumor suppressor menin by miR-421 promotes proliferation and migration of neuroblastoma. Tumour Biol. 35:10011–10017. 2014. View Article : Google Scholar : PubMed/NCBI
17	Liu H, Gao Y, Song D, Liu T and Feng Y: Correlation between microRNA-421 expression level and prognosis of gastric cancer. Int J Clin Exp Pathol. 8:15128–15132. 2015.PubMed/NCBI
18	Wu J, Li G, Yao Y, Wang Z, Sun W and Wang J: MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer. Biomarkers. 20:58–63. 2015. View Article : Google Scholar : PubMed/NCBI
19	Yang P, Zhang M, Liu X and Pu H: MicroRNA-421 promotes the proliferation and metastasis of gastric cancer cells by targeting claudin-11. Exp Ther Med. 14:2625–2632. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ge X, Liu X, Lin F, Li P, Liu K, Geng R, Dai C, Lin Y, Tang W, Wu Z, et al: MicroRNA-421 regulated by HIF-1alpha promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget. 7:24466–24482. 2016. View Article : Google Scholar : PubMed/NCBI
21	Hu TB, Chen HS, Cao MQ, Guo FD, Cheng XY, Han ZB and Li MQ: MicroRNA-421 inhibits caspase-10 expression and promotes breast cancer progression. Neoplasma. 65:49–54. 2018. View Article : Google Scholar : PubMed/NCBI
22	Cinegaglia NC, Andrade SC, Tokar T, Pinheiro M, Severino FE, Oliveira RA, Hasimoto EN, Cataneo DC, Cataneo AJ, Defaveri J, et al: Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma. Oncotarget. 7:28920–28934. 2016. View Article : Google Scholar : PubMed/NCBI
23	Chen Z, Yu W, Zhou Q, Zhang J, Jiang H, Hao D, Wang J, Zhou Z, He C and Xiao Z: A Novel lncRNA IHS promotes tumor proliferation and metastasis in HCC by Regulating the ERK- and AKT/GSK-3β-Signaling Pathways. Mol Ther Nucleic Acids. 16:707–720. 2019. View Article : Google Scholar : PubMed/NCBI
24	Kim SA, Kang OH and Kwon DY: Cryptotanshinone Induces Cell Cycle Arrest and Apoptosis of NSCLC Cells through the PI3K/Akt/GSK-3β Pathway. Int J Mol Sci. 19:27392018. View Article : Google Scholar
25	Chen Y, Liu X, Wang H, Liu S, Hu N and Li X: Akt regulated phosphorylation of GSK-3β/Cyclin D1, p21 and p27 contributes to cell proliferation through cell cycle progression from G1 to S/G2M Phase in low-dose arsenite exposed HaCat cells. Front Pharmacol. 10:11762019. View Article : Google Scholar : PubMed/NCBI
26	Coomans de Brachene A and Demoulin JB: FOXO transcription factors in cancer development and therapy. Cell Mol Life Sci. 73:1159–1172. 2016. View Article : Google Scholar : PubMed/NCBI
27	Chen D, Yang Y and Yang P: Quxie capsule inhibits colon tumor growth partially through foxo1-mediated apoptosis and immune modulation. Integr Cancer Ther. 18:15347354198463772019. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	van Tonder A, Joubert AM and Cromarty AD: Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays. BMC Res Notes. 8:472015. View Article : Google Scholar : PubMed/NCBI
30	Riffo-Campos AL, Riquelme I and Brebi-Mieville P: Tools for sequence-based miRNA target prediction: What to choose? Int J Mol Sci. 17:19872016. View Article : Google Scholar
31	Xie D, Shang C, Zhang H, Guo Y and Tong X: Up-regulation of miR-9 target CBX7 to regulate invasion ability of bladder transitional cell carcinoma. Med Sci Monit. 21:225–230. 2015. View Article : Google Scholar : PubMed/NCBI
32	Zuryn A, Litwiniec A, Gagat M, Drzewucka J, Gackowska L and Grzanka A: The influence of arsenic trioxide on the cell cycle, apoptosis and expression of cyclin D1 in the Jurkat cell line. Acta Histochem. 116:1350–1358. 2014. View Article : Google Scholar : PubMed/NCBI
33	Gongpan P, Lu Y, Wang F, Xu Y and Xiong W: AS160 controls eukaryotic cell cycle and proliferation by regulating the CDK inhibitor p21. Cell cycle (Georgetown Tex.). 15:1733–1741. 2016. View Article : Google Scholar
34	Fukuda Y, Kanbe M, Watanabe M, Dan K, Matsuzaki K, Kitanaka S and Miyata S: 3EZ,20Ac-ingenol, a catalytic inhibitor of topoisomerases, downregulates p-Akt and induces DSBs and apoptosis of DT40 cells. Arch Pharm Res. 36:1029–1038. 2013. View Article : Google Scholar : PubMed/NCBI
35	Mao Z, Zhou J, Luan J, Sheng W, Shen X and Dong X: Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells. Biomed Pharmacother. 68:179–183. 2014. View Article : Google Scholar : PubMed/NCBI